MoneyThe story, in brief
Eli Lilly signs $2bn deal for AI drug development with Hong Kong biotech
$2B. That's what Eli Lilly just committed to AI drug development—signaling where pharma sees the real ROI.
The KeyNews take
Why it matters
A Fortune 500 pharmaceutical giant betting $2B on AI-driven drug discovery with a Hong Kong biotech partner signals mainstream enterprise adoption of AI for high-stakes R&D. This is capital flowing toward applied AI outcomes, not infrastructure or models.
The key facts
5 to know$2B deal size
Eli Lilly (major pharma player) committing capital
Hong Kong biotech partner (geographic expansion of AI biotech)
AI drug development focus (vertical application)
Broader trend: pharma aggressively pursuing AI-enabled discovery in China region
Go to the source
Financial Times Technologyft.com
Publisher excerpt: Global pharmaceutical companies are aggressively searching for new medicines in China